This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-let-7b-5p | ABL1 | 0.6 | 0.0014 | -1.32 | 0 | miRNAWalker2 validate | -0.23 | 0 | NA | |
2 | hsa-miR-149-5p | ABL1 | 2.94 | 0 | -1.32 | 0 | miRNAWalker2 validate | -0.14 | 0 | NA | |
3 | hsa-miR-484 | ABL1 | 1.82 | 0 | -1.32 | 0 | miRNAWalker2 validate | -0.28 | 0 | NA | |
4 | hsa-miR-181a-5p | ATM | 2.3 | 0 | -0.69 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.13 | 3.0E-5 | 24531888; 27150990; 21102523; 26113450; 23656790 | Ataxia-telangiectasia mutation ATM was predicted as a target gene of miR-181a with bioinformatics analysis and was verified by lucifersae reporter assay; A luciferase reporter assay demonstrated that ATM was a direct target of miR-181a miR-181a mimics transfection down regulated ATM mRNA and protein expression; There was inverse correlation between miR-181a and ATM protein expression in gastric cancer and normal gastric tissues; Our study demonstrates that over-expression of miR-181a might be involved in development of gastric cancer by promoting proliferation and inhibiting apoptosis probably through directly targeting ATM miR-181a modulation may be a potential strategy for the development of miRNA-based therapy of gastric cancer;MiR 181a Promotes Proliferation of Human Acute Myeloid Leukemia Cells by Targeting ATM; Dual luciferase reporter gene assay showed that miR-181a significantly suppressed the reporter gene activity containing ATM 3'-UTR by about 56.8% P < 0.05 but it didn't suppress the reporter gene activity containing 3'-UTR ATM mutation; Western blot showed that miR-181a significantly downregulated the expression of ATM in human leukemia cells; It is also found that miR-181a was significantly increased in AML which showed a negative correlation with ATM expression; miR-181a promotes cell proliferation in AML by regulating the tumor suppressor ATM thus it plays the role as oncogene in pathogenesis of AML;Ataxia telangiectasia mutated ATM a target gene of miR-181 exhibited reduced expression in mammospheres and upon TGF-β treatment;miR 181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM; Pediatric AML patients and healthy controls were enrolled and the expression of miR-181a and ataxia telangiectasia mutated ATM in tissues were examined using quantitative PCR; Moreover cell proliferation and cell cycle were evaluated in several cell lines HL60 NB4 and K562 by using flow cytometry after transfected with miR-181a mimics and inhibitors or ATM siRNA and control siRNA; Finally ATM as the potential target protein of miR-181a was examined; We found that miR-181a was significantly increased in pediatric AML which showed an inverse association with ATM expression; Luciferase activity of the reporter construct identified ATM as the direct molecular target of miR-181a; The results revealed novel mechanism through which miR-181a regulates G1/S transition and cell proliferation in pediatric AML by regulating the tumor suppressor ATM providing insights into the molecular mechanism in pediatric AML;We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers and their expression correlates inversely with ATM levels |
5 | hsa-miR-18a-5p | ATM | 3.79 | 0 | -0.69 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.13 | 0 | 23437304; 25963391; 23857602; 23229340 | MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases |
6 | hsa-miR-19b-3p | ATM | 2.5 | 0 | -0.69 | 1.0E-5 | miRNAWalker2 validate | -0.17 | 0 | NA | |
7 | hsa-miR-92a-3p | ATM | 2.06 | 0 | -0.69 | 1.0E-5 | miRNAWalker2 validate | -0.17 | 0 | NA | |
8 | hsa-miR-335-5p | CCNA1 | 1.77 | 0 | -0.8 | 0.29528 | miRNAWalker2 validate | -0.25 | 0.00952 | NA | |
9 | hsa-miR-23b-3p | CCNB2 | -0.25 | 0.1502 | 3.44 | 0 | miRNAWalker2 validate | -0.35 | 8.0E-5 | NA | |
10 | hsa-miR-106b-5p | CCND1 | 2.47 | 0 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.19 | 0.01301 | NA | |
11 | hsa-miR-15b-5p | CCND1 | 1.57 | 0 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.0019 | NA | |
12 | hsa-miR-195-5p | CCND1 | -1.45 | 0 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.23 | 0.00278 | 21350001; 26631043; 25823925 | Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma |
13 | hsa-miR-19a-3p | CCND1 | 3.42 | 0 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.13 | 0.03027 | 25985117 | Moreover miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression |
14 | hsa-miR-19b-1-5p | CCND1 | 2.58 | 0 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.15 | 0.02853 | NA | |
15 | hsa-miR-338-3p | CCND1 | 0.45 | 0.14458 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.15 | 0.02359 | NA | |
16 | hsa-miR-365a-3p | CCND1 | -0.04 | 0.85911 | 0.08 | 0.84033 | miRNAWalker2 validate; miRTarBase | -0.21 | 0.02249 | NA | |
17 | hsa-miR-374b-5p | CCND1 | 0.07 | 0.72267 | 0.08 | 0.84033 | miRNAWalker2 validate | -0.42 | 0.00013 | NA | |
18 | hsa-miR-92a-3p | CCND1 | 2.06 | 0 | 0.08 | 0.84033 | miRNAWalker2 validate | -0.19 | 0.02573 | NA | |
19 | hsa-let-7a-5p | CCND2 | 0.62 | 3.0E-5 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.5 | 0.0001 | 20418948 | MicroRNA let 7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2 |
20 | hsa-let-7b-5p | CCND2 | 0.6 | 0.0014 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase | -0.37 | 0.0002 | NA | |
21 | hsa-miR-106b-5p | CCND2 | 2.47 | 0 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase | -0.72 | 0 | NA | |
22 | hsa-miR-141-3p | CCND2 | 5.02 | 0 | -2.43 | 0 | TargetScan | -0.34 | 0 | NA | |
23 | hsa-miR-15a-5p | CCND2 | 2.35 | 0 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase | -0.56 | 0 | NA | |
24 | hsa-miR-16-5p | CCND2 | 1.76 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.62 | 0 | NA | |
25 | hsa-miR-17-5p | CCND2 | 3.27 | 0 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.58 | 0 | NA | |
26 | hsa-miR-182-5p | CCND2 | 3.54 | 0 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase | -0.42 | 0 | NA | |
27 | hsa-miR-19b-3p | CCND2 | 2.5 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.64 | 0 | NA | |
28 | hsa-miR-20a-5p | CCND2 | 3.16 | 0 | -2.43 | 0 | miRNAWalker2 validate; miRTarBase | -0.55 | 0 | NA | |
29 | hsa-miR-301a-3p | CCND2 | 2.81 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.49 | 0 | NA | |
30 | hsa-miR-320a | CCND2 | 0.44 | 0.03902 | -2.43 | 0 | miRNAWalker2 validate | -0.37 | 4.0E-5 | NA | |
31 | hsa-miR-324-3p | CCND2 | 2.09 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.57 | 0 | NA | |
32 | hsa-miR-335-5p | CCND2 | 1.77 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.2 | 8.0E-5 | NA | |
33 | hsa-miR-378a-3p | CCND2 | -0.11 | 0.71619 | -2.43 | 0 | miRNAWalker2 validate | -0.26 | 2.0E-5 | NA | |
34 | hsa-miR-423-5p | CCND2 | 0.96 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.68 | 0 | NA | |
35 | hsa-miR-877-5p | CCND2 | 2.95 | 0 | -2.43 | 0 | miRNAWalker2 validate | -0.36 | 0 | NA | |
36 | hsa-miR-96-5p | CCND2 | 4.89 | 0 | -2.43 | 0 | TargetScan | -0.38 | 0 | NA | |
37 | hsa-miR-27b-3p | CCND3 | 0.2 | 0.29563 | 0.14 | 0.39731 | miRNAWalker2 validate | -0.13 | 0.00231 | NA | |
38 | hsa-miR-23b-3p | CDC20 | -0.25 | 0.1502 | 3.89 | 0 | miRNAWalker2 validate | -0.44 | 1.0E-5 | NA | |
39 | hsa-miR-30a-5p | CDC20 | -0.88 | 0.00051 | 3.89 | 0 | miRNAWalker2 validate | -0.14 | 0.03688 | NA | |
40 | hsa-let-7a-5p | CDC25B | 0.62 | 3.0E-5 | 0.78 | 0.00479 | miRNAWalker2 validate | -0.2 | 0.02874 | NA | |
41 | hsa-miR-141-3p | CDC25B | 5.02 | 0 | 0.78 | 0.00479 | TargetScan | -0.12 | 0 | NA | |
42 | hsa-miR-23b-3p | CDK2 | -0.25 | 0.1502 | 0.94 | 0 | miRNAWalker2 validate | -0.11 | 0.0284 | NA | |
43 | hsa-miR-103a-3p | CDK6 | 1.44 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate | -0.74 | 0 | NA | |
44 | hsa-miR-107 | CDK6 | 1.31 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase | -0.54 | 0 | 19407485; 22491216; 21264532; 19688090 | Enforced expression of miR-107 in MiaPACA-2 and PANC-1 cells downregulated in vitro growth and this was associated with repression of the putative miR-107 target cyclin-dependent kinase 6 thereby providing a functional basis for the epigenetic inactivation of this miRNA in pancreatic cancer;Levels of known miR-107 targets protein kinase Cε PKCε cyclin-dependent kinase 6 CDK6 and hypoxia-inducible factor 1-β HIF1-β decreased following NP/pre-miR-107 treatment;We have identified miR-107 as a potential regulator of CDK6 expression; A bioinformatics search revealed a putative target site for miR-107 within the CDK6 3' untranslated region; Expression of miR-107 in gastric cancer cell lines was found inversely correlated with CDK6 expression; miR-107 could significantly suppress CDK6 3' UTR luciferase reporter activity and this effect was not detectable when the putative 3' UTR target site was mutated; Consistent with the results of the reporter assay ectopic expression of miR-107 reduced both mRNA and protein expression levels of CDK6 inhibited proliferation induced G1 cell cycle arrest and blocked invasion of the gastric cancer cells; Our results suggest that miR-107 may have a tumor suppressor function by directly targeting CDK6 to inhibit the proliferation and invasion activities of gastric cancer cells;Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6 |
45 | hsa-miR-141-3p | CDK6 | 5.02 | 0 | -0.77 | 0.06479 | TargetScan | -0.28 | 0 | NA | |
46 | hsa-miR-16-5p | CDK6 | 1.76 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase | -0.21 | 0.02241 | NA | |
47 | hsa-miR-17-5p | CDK6 | 3.27 | 0 | -0.77 | 0.06479 | TargetScan | -0.17 | 0.00702 | NA | |
48 | hsa-miR-185-5p | CDK6 | 2.34 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate | -0.42 | 0 | 19688090 | Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6 |
49 | hsa-miR-191-5p | CDK6 | 2.3 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase | -0.71 | 0 | NA | |
50 | hsa-miR-218-5p | CDK6 | -0.57 | 0.0552 | -0.77 | 0.06479 | miRNAWalker2 validate | -0.15 | 0.02404 | 23996750 | Ectopic expression of miR-218 in HepG2 cells resulted in suppressed cell proliferation and enhanced cell apoptosis as well as the down-regulation of Bmi-1 and CDK6 mRNA and protein expressions P<0.05; The low-expression of miR-218 is correlated with malignant clinicopathological characteristics of HCC and miR-218 may inhibit cell proliferation and promote cell apoptosis by down-regulating Bmi-1 and CDK6 in HCC |
51 | hsa-miR-29b-3p | CDK6 | 1.66 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase | -0.22 | 0.00223 | 23245396; 25472644; 26180082; 23591808; 27230400; 20086245 | The IFN-γ-induced G1-arrest of melanoma cells involves down-regulation of CDK6 which we proved to be a direct target of miR-29 in these cells;Moreover miR-29b inhibited the expression of MCL1 and CDK6;Knockdown of NTSR1 increased the expression of miR-29b-1 and miR-129-3p which were responsible for the decreased CDK6 expression;Here we have identified the oncogene cyclin-dependent protein kinase 6 CDK6 as a direct target of miR-29b in lung cancer;MiR 29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6; In this study we investigated the role of miR-29b as a novel regulator of CDK6 using bioinformatics methods; We demonstrated that CDK6 can be downregulated by miR-29b via binding to the 3'-UTR region in osteosarcoma cells; Furthermore we identified an inverse correlation between miR-29b and CDK6 protein levels in osteosarcoma tissues; The results revealed that miR-29b acts as a tumor suppressor of osteosarcoma by targeting CDK6 in the proliferation and migration processes;microRNA expression profile and identification of miR 29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma; Furthermore we demonstrate miR-29 inhibition of CDK6 protein and mRNA levels by direct binding to 3'-untranslated region; Inverse correlation between miR-29 and CDK6 was observed in MCL |
52 | hsa-miR-29c-3p | CDK6 | -0.01 | 0.971 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase | -0.58 | 0 | 26396669 | Furthermore through qPCR and Western blot assays confirmed that overexpression of miR-29c reduced CDK6 mRNA and protein levels; miR-29c could inhibit the proliferation migration and invasion of bladder cancer cells via regulating CDK6 |
53 | hsa-miR-34a-5p | CDK6 | 1.9 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase | -0.52 | 0 | 21702042; 26104764 | Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004 |
54 | hsa-miR-501-3p | CDK6 | 1.83 | 0 | -0.77 | 0.06479 | TargetScan | -0.41 | 0 | NA | |
55 | hsa-let-7f-5p | CDKN1A | 0.5 | 0.00356 | -1.29 | 0 | miRNAWalker2 validate | -0.24 | 0.00297 | NA | |
56 | hsa-miR-106a-5p | CDKN1A | 2.49 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.13 | 0.00055 | 25510666 | After prediction with online software we further used dual-luciferase reporter gene assay to ensure that TP53INP1 and CDKN1A might be the direct targets of miR-106a |
57 | hsa-miR-106b-5p | CDKN1A | 2.47 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.3 | 0 | NA | |
58 | hsa-miR-17-5p | CDKN1A | 3.27 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.17 | 3.0E-5 | 26482648; 24989082 | The low expressions of miR-17 and miR-92 families can maintain cisplatin resistance through the regulation of CDKN1A and RAD21;According to PicTar and Miranda algorithms which predicted CDKN1A p21 as a putative target of miR-17 a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA |
59 | hsa-miR-182-5p | CDKN1A | 3.54 | 0 | -1.29 | 0 | miRNAWalker2 validate | -0.11 | 0.00142 | NA | |
60 | hsa-miR-20a-5p | CDKN1A | 3.16 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.17 | 7.0E-5 | 26012475 | Using the poorly tumorigenic and TGF-β-sensitive FET cell line that expresses low miR-20a levels we first confirmed that miR-20a downmodulated CDKN1A expression both at mRNA and protein level through direct binding to its 3'-UTR; Moreover besides modulating CDKN1A miR-20a blocked TGF-β-induced transactivation of its promoter without affecting the post-receptor activation of Smad3/4 effectors directly; Finally miR-20a abrogated the TGF-β-mediated c-Myc repression a direct inhibitor of the CDKN1A promoter activation most likely by reducing the expression of specific MYC-regulating genes from the Smad/E2F-based core repressor complex |
61 | hsa-miR-20b-5p | CDKN1A | 2.08 | 1.0E-5 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.11 | 7.0E-5 | NA | |
62 | hsa-miR-28-5p | CDKN1A | 0.23 | 0.07429 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.56 | 0 | NA | |
63 | hsa-miR-335-5p | CDKN1A | 1.77 | 0 | -1.29 | 0 | miRNAWalker2 validate | -0.15 | 2.0E-5 | NA | |
64 | hsa-miR-345-5p | CDKN1A | 3.64 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.21 | 0 | NA | |
65 | hsa-miR-363-3p | CDKN1A | 1.51 | 0.00021 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.12 | 0.00029 | NA | |
66 | hsa-miR-423-3p | CDKN1A | 2.58 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.2 | 6.0E-5 | NA | |
67 | hsa-miR-503-5p | CDKN1A | 3.67 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.11 | 0.00188 | NA | |
68 | hsa-miR-505-5p | CDKN1A | 1.89 | 0 | -1.29 | 0 | miRNAWalker2 validate | -0.2 | 3.0E-5 | NA | |
69 | hsa-miR-93-5p | CDKN1A | 3.04 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.23 | 0 | 25633810 | MicroRNA 93 activates c Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A; We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumor-suppressor genes PTEN and CDKN1A respectivelyand inhibited their expression; We concluded that miR-93 stimulated cell proliferation migration and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC |
70 | hsa-miR-942-5p | CDKN1A | 2.35 | 0 | -1.29 | 0 | miRNAWalker2 validate | -0.26 | 0 | NA | |
71 | hsa-miR-96-5p | CDKN1A | 4.89 | 0 | -1.29 | 0 | miRNAWalker2 validate; miRTarBase | -0.13 | 2.0E-5 | 26582573 | Upregulation of microRNA 96 and its oncogenic functions by targeting CDKN1A in bladder cancer; Bioinformatics prediction combined with luciferase reporter assay were used to verify whether the cyclin-dependent kinase inhibitor CDKN1A was a potential target gene of miR-96; According to the data of miRTarBase CDKN1A might be a candidate target gene of miR-96; In addition luciferase reporter and Western blot assays respectively demonstrated that miR-96 could bind to the putative seed region in CDKN1A mRNA 3'UTR and significantly reduce the expression level of CDKN1A protein; Moreover we found that the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines which was consistent with the findings observed following the introduction of CDKN1A cDNA without 3'UTR restored miR-96; Upregulation of miR-96 may contribute to aggressive malignancy partly through suppressing CDKN1A protein expression in BC cells |
72 | hsa-miR-98-5p | CDKN1A | 1.11 | 0 | -1.29 | 0 | miRNAWalker2 validate | -0.25 | 0.00026 | NA | |
73 | hsa-miR-221-3p | CDKN1B | 0.45 | 0.09098 | 0.11 | 0.45385 | miRNAWalker2 validate; miRTarBase | -0.11 | 6.0E-5 | 23637992; 19953484; 23939688; 19126397; 20146005; 23967190; 17569667; 22992757; 17721077; 20461750 | miR-221 knockdown not only blocked cell cycle progression induced cell apoptosis and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;A Slug/miR-221 network has been suggested linking miR-221 activity with the downregulation of a Slug repressor leading to Slug/miR-221 upregulation and p27Kip1 downregulation; Interference with this process can be achieved using antisense miRNA antagomiR molecules targeting miR-221 inducing the downregulation of Slug and the upregulation of p27Kip1;Moreover a series of functional assays demonstrated that mir-221 could directly inhibit cKit p27Kip1 and possibly other pivotal proteins in melanoma;Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27Kip1 p21WAF1/Cip1and TGF-β1 by in situ hybridization and immunohistochemistry respectively; Real time qRT-PCR was used to investigate miR-221 and p27Kip1 transcripts in different clinical stages; In result miR-221 and TGF-β1 are frequently up-regulated in HCC while p27Kip1 and p21WAF1/Cip1 proteins are frequently down-regulated; In conclusion miR-221 is important in tumorigenesis of HCC possibly by specifically down-regulating p27Kip1 a cell-cycle inhibitor;Additionally the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;Peptide nucleic acids targeting miR 221 modulate p27Kip1 expression in breast cancer MDA MB 231 cells; Targeting miR-221 by PNA resulted in i lowering of the hybridization levels of miR-221 measured by RT-qPCR ii upregulation of p27Kip1 gene expression measured by RT-qPCR and western blot analysis;Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27Kip1 levels and enhanced expression of the luciferase reporter gene fused to the p27Kip1 3'UTR;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression |
74 | hsa-miR-24-3p | CDKN1B | 1 | 0 | 0.11 | 0.45385 | miRNAWalker2 validate | -0.16 | 3.0E-5 | 26847530; 26044523 | The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 CDKN1B and p16 CDK2NA was investigated;With the bioinformatic method we further identified that p27Kip1 is a direct target of miR-24-3p and its protein level was negatively regulated by miR-24-3p |
75 | hsa-miR-221-3p | CDKN1C | 0.45 | 0.09098 | -1.45 | 4.0E-5 | miRNAWalker2 validate; miRTarBase | -0.25 | 0.00011 | 20461750 | miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01 |
76 | hsa-miR-222-3p | CDKN1C | 0.85 | 0.00267 | -1.45 | 4.0E-5 | miRNAWalker2 validate; miRTarBase | -0.25 | 4.0E-5 | 20461750 | miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01 |
77 | hsa-miR-25-3p | CDKN1C | 1.36 | 0 | -1.45 | 4.0E-5 | miRNAWalker2 validate; miRTarBase | -0.16 | 0.04449 | NA | |
78 | hsa-miR-335-5p | CDKN1C | 1.77 | 0 | -1.45 | 4.0E-5 | miRNAWalker2 validate | -0.1 | 0.02146 | NA | |
79 | hsa-miR-10b-5p | CDKN2A | -0.16 | 0.55501 | 2.5 | 0.00259 | miRNAWalker2 validate; miRTarBase | -0.4 | 0.01005 | NA | |
80 | hsa-miR-34a-5p | CDKN2C | 1.9 | 0 | 0.23 | 0.43313 | miRNAWalker2 validate | -0.22 | 6.0E-5 | NA | |
81 | hsa-miR-23b-3p | E2F1 | -0.25 | 0.1502 | 2.3 | 0 | miRNAWalker2 validate | -0.37 | 1.0E-5 | NA | |
82 | hsa-miR-125b-5p | E2F3 | -1.16 | 0.00029 | 0.86 | 0.00039 | miRNAWalker2 validate; miRTarBase | -0.14 | 9.0E-5 | 20549700; 22523546 | E2F3 which was critical for G1/S transition and was overexpressed in most of poor-differentiated bladder cancers was identified as a target of miR-125b by luciferase assay; Introduction of miR-125b could reduce the expression of E2F3 protein but not the E2F3 mRNA;Moreover we demonstrated that the E2F3 was a direct target of miR-125b in breast cancer cells |
83 | hsa-miR-140-5p | EP300 | 0.84 | 4.0E-5 | -0.26 | 0.13065 | miRNAWalker2 validate | -0.12 | 0.00415 | NA | |
84 | hsa-miR-193b-3p | EP300 | 2.26 | 0 | -0.26 | 0.13065 | miRNAWalker2 validate | -0.11 | 8.0E-5 | NA | |
85 | hsa-miR-374a-5p | GADD45A | 0.48 | 0.0043 | -0.84 | 0.00014 | miRNAWalker2 validate; miRTarBase | -0.16 | 0.01486 | NA | |
86 | hsa-miR-145-5p | HDAC2 | -1.55 | 0 | 0.31 | 0.0174 | miRNAWalker2 validate | -0.11 | 0 | 23499894 | MiR 145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer; Ectopic expression of miRNA mimics evidenced that miR-145 suppresses HDAC2 expression in HCC cells; In conclusion we suggest that loss or suppression of miR-145 may cause aberrant overexpression of HDAC2 and promote HCC tumorigenesis |
87 | hsa-let-7f-5p | MYC | 0.5 | 0.00356 | -1.77 | 0 | miRNAWalker2 validate | -0.3 | 0.00594 | NA | |
88 | hsa-let-7g-5p | MYC | 1.2 | 0 | -1.77 | 0 | miRNAWalker2 validate; miRTarBase | -0.65 | 0 | NA | |
89 | hsa-miR-320a | MYC | 0.44 | 0.03902 | -1.77 | 0 | miRNAWalker2 validate | -0.27 | 0.00203 | 25736597 | Furthermore progesterone P4 promoted the expression of miR-320a by repressing c-Myc expression while estrogen E2 exerted the opposite effect |
90 | hsa-miR-320b | MYC | 1.56 | 0 | -1.77 | 0 | miRNAWalker2 validate | -0.21 | 0.00143 | 26487644 | miR 320b suppresses cell proliferation by targeting c Myc in human colorectal cancer cells; Overexpression of miR-320b in CRC cells was statistically correlated with a decrease of cell growth in vitro and in vivo while c-MYC was identified as a target gene of miR-320b in CRC; Furthermore it was found that up-regulation of c-Myc can attenuate the effects induced by miR-320b; Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology of CRC proliferation and identifies miR-320b as a novel therapeutic target for the treatment of CRC |
91 | hsa-miR-335-5p | MYC | 1.77 | 0 | -1.77 | 0 | miRNAWalker2 validate | -0.16 | 0.00141 | NA | |
92 | hsa-miR-34a-5p | MYC | 1.9 | 0 | -1.77 | 0 | miRNAWalker2 validate; miRTarBase | -0.36 | 0 | 25572695; 25686834; 21460242; 22159222; 23640973; 22830357; 22235332 | The c-Myc and CD44 were confirmed as direct targets of miR-34a in EJ cell apoptosis induced by PRE;miR 34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c Myc pathway;Myc mediated repression of microRNA 34a promotes high grade transformation of B cell lymphoma by dysregulation of FoxP1;MicroRNA 34a suppresses malignant transformation by targeting c Myc transcriptional complexes in human renal cell carcinoma; We investigated the functional effects of microRNA-34a miR-34a on c-Myc transcriptional complexes in renal cell carcinoma; miR-34a down-regulated expression of multiple oncogenes including c-Myc by targeting its 3' untranslated region which was revealed by luciferase reporter assays; Our results demonstrate that miR-34a suppresses assembly and function of the c-Myc complex that activates or elongates transcription indicating a novel role of miR-34a in the regulation of transcription by c-Myc;Among them miR-34a was also associated with poor prognosis in 2 independent series of leukemic and nodal MCL and in cooperation with high expression of the MYC oncogene;We report that miR-34a did not inhibit cell proliferation notwithstanding a marked down-regulation of c-MYC;MicroRNA 34a modulates c Myc transcriptional complexes to suppress malignancy in human prostate cancer cells; We studied the functional effects of miR-34a on c-Myc transcriptional complexes in PC-3 prostate cancer cells; miR-34a downregulated expression of c-Myc oncogene by targeting its 3' UTR as shown by luciferase reporter assays; This is the first report to document that miR-34a suppresses assembly and function of the c-Myc-Skp2-Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription of various genes suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex |
93 | hsa-miR-423-5p | MYC | 0.96 | 0 | -1.77 | 0 | miRNAWalker2 validate | -0.59 | 0 | NA | |
94 | hsa-miR-429 | MYC | 4.49 | 0 | -1.77 | 0 | miRNAWalker2 validate | -0.27 | 0 | 21684154; 24633485 | miR 429 modulates the expression of c myc in human gastric carcinoma cells; SGC-7901 gastric cancer cells were transfected with miR-429 mimics and endogenous c-myc expression was detected by western blots; We performed functional assays using the 3'UTR of the c-myc gene as a miR-429 target in a luciferase reporter assay system; miR-429 significantly downregulated endogenous c-myc expression in SGC-7901 cells; Action of miR/429 on c-myc 3'UTR was confirmed; c-myc is an important miR-429 target gene;It is known that miR-429 is down-regulated and functions as a tumor suppressor by targeting c-myc and PLGG1 in gastric and breast cancer |
95 | hsa-miR-744-5p | MYC | 1.48 | 0 | -1.77 | 0 | miRNAWalker2 validate | -0.25 | 0.00044 | 24991193 | Decrease expression of microRNA 744 promotes cell proliferation by targeting c Myc in human hepatocellular carcinoma; Quantitative reverse-transcription polymerase chain reaction qRT-PCR was conducted to detect the expression of miR-744 and Immunohistochemistry was performed to detect expression of c-Myc in HCC specimens and adjacent normal tissues; Luciferase reporter assays was performed to confirm whether miR-744 regulated the expression of c-Myc; Luciferase assay and Western blot analysis revealed that c-Myc is a direct target of miR-744; Down-regulation of miR-744 and up-regulation of c-Myc were detected in HCC specimens compared with adjacent normal tissues; Moreover restoration of miR-744 rescues c-Myc induced HCC proliferation; Our data suggest that miR-744 exerts its tumor suppressor function by targeting c-Myc leading to the inhibition of HCC cell growth |
96 | hsa-miR-98-5p | MYC | 1.11 | 0 | -1.77 | 0 | miRNAWalker2 validate; miRTarBase | -0.6 | 0 | NA | |
97 | hsa-miR-106a-5p | RB1 | 2.49 | 0 | -0.45 | 0.06418 | miRNAWalker2 validate; miRTarBase | -0.21 | 0 | NA | |
98 | hsa-miR-106b-5p | RB1 | 2.47 | 0 | -0.45 | 0.06418 | miRNAWalker2 validate; miRTarBase | -0.18 | 8.0E-5 | NA | |
99 | hsa-miR-17-5p | RB1 | 3.27 | 0 | -0.45 | 0.06418 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.18 | 0 | NA | |
100 | hsa-miR-192-5p | RB1 | 2.69 | 0 | -0.45 | 0.06418 | miRNAWalker2 validate; miRTarBase | -0.15 | 1.0E-5 | NA | |
101 | hsa-miR-20a-5p | RB1 | 3.16 | 0 | -0.45 | 0.06418 | miRNAWalker2 validate; miRTarBase | -0.18 | 0 | NA | |
102 | hsa-miR-93-5p | RB1 | 3.04 | 0 | -0.45 | 0.06418 | miRNAWalker2 validate | -0.17 | 1.0E-5 | NA | |
103 | hsa-miR-155-5p | SMAD3 | 1.2 | 0.00086 | -0.15 | 0.56924 | miRNAWalker2 validate | -0.17 | 0 | 27626488 | Here we demonstrated that TGF-β1 elevated the expression of miR-155 in colorectal cancer cells through SMAD3 and SMAD4 |
104 | hsa-miR-18a-5p | SMAD3 | 3.79 | 0 | -0.15 | 0.56924 | miRNAWalker2 validate | -0.14 | 6.0E-5 | 23249750 | The unexpected effects of miR-18a on CTGF transcription are mediated in part by direct targeting of Smad3 and ensuing weakening of TGFβ signaling |
105 | hsa-miR-186-5p | SMAD4 | 1.47 | 0 | -0.59 | 0 | miRNAWalker2 validate | -0.11 | 0.00087 | NA | |
106 | hsa-miR-320a | SMC1A | 0.44 | 0.03902 | 0.04 | 0.7733 | miRNAWalker2 validate | -0.12 | 0.00036 | NA | |
107 | hsa-miR-26b-5p | STAG1 | 0.89 | 0 | -0.25 | 0.20245 | miRNAWalker2 validate | -0.17 | 0.00045 | NA | |
108 | hsa-miR-21-5p | STAG2 | 2.74 | 0 | -0.34 | 0.12258 | miRNAWalker2 validate | -0.12 | 0.01253 | NA | |
109 | hsa-miR-744-5p | TGFB1 | 1.48 | 0 | -0 | 0.99941 | miRNAWalker2 validate | -0.23 | 1.0E-5 | NA | |
110 | hsa-miR-141-3p | TGFB2 | 5.02 | 0 | -1.2 | 0.00331 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.36 | 0 | NA | |
111 | hsa-miR-29b-3p | TGFB2 | 1.66 | 0 | -1.2 | 0.00331 | miRTarBase | -0.23 | 0.00122 | NA | |
112 | hsa-miR-335-5p | TGFB2 | 1.77 | 0 | -1.2 | 0.00331 | miRNAWalker2 validate | -0.25 | 0 | NA | |
113 | hsa-miR-10a-5p | TGFB3 | 1.15 | 0.00372 | -1.92 | 0 | miRNAWalker2 validate | -0.42 | 0 | NA | |
114 | hsa-miR-29b-3p | TGFB3 | 1.66 | 0 | -1.92 | 0 | miRTarBase | -0.4 | 0 | NA | |
115 | hsa-miR-221-3p | TP53 | 0.45 | 0.09098 | 0.17 | 0.48779 | miRNAWalker2 validate | -0.12 | 0.01057 | 20880178; 24324033 | Circulating miR 221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression; The correlation between miR-221 levels and protein levels of p53 CEA ER and PR clinicopathological features or overall survival was analyzed; The immunohistochemistry analysis demonstrates a significant correlation between plasma miR-221 level and p53 expression; The direct amplification of plasma miR-221 can be used as a potential noninvasive molecular marker for diagnosis and prognosis of CRC and is correlated with p53 expression;Interestingly miR-221 can activate the p53/mdm2 axis by inhibiting MDM2 and in turn p53 activation contributes to miR-221 enhanced expression; Moreover by modulating the p53 axis miR-221 impacts cell-cycle progression and apoptotic response to doxorubicin in hepatocellular carcinoma-derived cell lines; These data were confirmed in clinical specimens of hepatocellular carcinoma in which elevated miR-221 expression was associated with the simultaneous presence of wild-type p53 and DNA hypomethylation |
116 | hsa-miR-222-3p | TP53 | 0.85 | 0.00267 | 0.17 | 0.48779 | miRNAWalker2 validate | -0.12 | 0.0059 | NA | |
117 | hsa-miR-155-5p | WEE1 | 1.2 | 0.00086 | -1.41 | 0 | miRNAWalker2 validate | -0.12 | 3.0E-5 | NA | |
118 | hsa-miR-27a-3p | WEE1 | 1.67 | 0 | -1.41 | 0 | miRTarBase | -0.15 | 0.00064 | NA | |
119 | hsa-miR-424-5p | WEE1 | 1.62 | 0 | -1.41 | 0 | miRNAWalker2 validate; miRTarBase | -0.13 | 0.00073 | NA | |
120 | hsa-miR-26a-5p | YWHAE | 0.05 | 0.75263 | 0.51 | 0.00018 | miRNAWalker2 validate | -0.17 | 0.00016 | NA | |
121 | hsa-miR-103a-3p | YWHAH | 1.44 | 0 | -0.04 | 0.78793 | miRNAWalker2 validate | -0.16 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CELL CYCLE | 31 | 1316 | 6.724e-33 | 3.129e-29 |
2 | CELL CYCLE PROCESS | 28 | 1081 | 1.102e-29 | 2.564e-26 |
3 | REGULATION OF CELL CYCLE | 27 | 949 | 2.077e-29 | 3.221e-26 |
4 | NEGATIVE REGULATION OF CELL CYCLE | 21 | 433 | 1.202e-26 | 1.398e-23 |
5 | MITOTIC CELL CYCLE | 24 | 766 | 1.957e-26 | 1.821e-23 |
6 | CELL CYCLE ARREST | 15 | 154 | 2.809e-23 | 2.178e-20 |
7 | POSITIVE REGULATION OF CELL CYCLE | 17 | 332 | 1.269e-21 | 8.435e-19 |
8 | REGULATION OF MITOTIC CELL CYCLE | 18 | 468 | 1.007e-20 | 5.857e-18 |
9 | CELL CYCLE PHASE TRANSITION | 15 | 255 | 6.545e-20 | 3.384e-17 |
10 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 14 | 199 | 1.134e-19 | 5.276e-17 |
11 | REGULATION OF PROTEIN MODIFICATION PROCESS | 25 | 1710 | 1.336e-19 | 5.65e-17 |
12 | REGULATION OF CELL PROLIFERATION | 23 | 1496 | 3.725e-18 | 1.444e-15 |
13 | MITOTIC CELL CYCLE CHECKPOINT | 12 | 139 | 5.698e-18 | 2.04e-15 |
14 | CELL DIVISION | 16 | 460 | 1.288e-17 | 4.28e-15 |
15 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 23 | 1618 | 2.123e-17 | 6.584e-15 |
16 | REGULATION OF CELL CYCLE ARREST | 11 | 108 | 2.528e-17 | 7.351e-15 |
17 | NEGATIVE REGULATION OF CELL PROLIFERATION | 17 | 643 | 9.006e-17 | 2.465e-14 |
18 | REGULATION OF TRANSFERASE ACTIVITY | 19 | 946 | 1.103e-16 | 2.851e-14 |
19 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 13 | 247 | 1.314e-16 | 3.218e-14 |
20 | POSITIVE REGULATION OF CELL CYCLE ARREST | 10 | 85 | 1.873e-16 | 4.358e-14 |
21 | REGULATION OF CELL CYCLE PROCESS | 16 | 558 | 2.712e-16 | 6.008e-14 |
22 | CELL CYCLE CHECKPOINT | 12 | 194 | 3.381e-16 | 7.151e-14 |
23 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 10 | 96 | 6.668e-16 | 1.349e-13 |
24 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 10 | 98 | 8.261e-16 | 1.602e-13 |
25 | POSITIVE REGULATION OF CELL DEATH | 16 | 605 | 9.634e-16 | 1.793e-13 |
26 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 12 | 214 | 1.11e-15 | 1.987e-13 |
27 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 16 | 616 | 1.277e-15 | 2.201e-13 |
28 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 19 | 1087 | 1.414e-15 | 2.35e-13 |
29 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 21 | 1492 | 1.561e-15 | 2.505e-13 |
30 | CELL CYCLE G1 S PHASE TRANSITION | 10 | 111 | 2.995e-15 | 4.496e-13 |
31 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 10 | 111 | 2.995e-15 | 4.496e-13 |
32 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 19 | 1135 | 3.113e-15 | 4.527e-13 |
33 | REGULATION OF CELL CYCLE PHASE TRANSITION | 13 | 321 | 3.958e-15 | 5.581e-13 |
34 | G1 DNA DAMAGE CHECKPOINT | 9 | 73 | 4.515e-15 | 6.179e-13 |
35 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 10 | 146 | 4.941e-14 | 6.569e-12 |
36 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 10 | 147 | 5.296e-14 | 6.845e-12 |
37 | MITOTIC DNA INTEGRITY CHECKPOINT | 9 | 100 | 8.571e-14 | 1.078e-11 |
38 | RESPONSE TO OXYGEN LEVELS | 12 | 311 | 9.805e-14 | 1.201e-11 |
39 | RESPONSE TO ABIOTIC STIMULUS | 17 | 1024 | 1.899e-13 | 2.266e-11 |
40 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 17 | 1036 | 2.294e-13 | 2.603e-11 |
41 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 17 | 1036 | 2.294e-13 | 2.603e-11 |
42 | REGULATION OF KINASE ACTIVITY | 15 | 776 | 9.371e-13 | 1.038e-10 |
43 | POSITIVE REGULATION OF CELL PROLIFERATION | 15 | 814 | 1.862e-12 | 1.969e-10 |
44 | REGULATION OF ORGANELLE ORGANIZATION | 17 | 1178 | 1.823e-12 | 1.969e-10 |
45 | DNA INTEGRITY CHECKPOINT | 9 | 146 | 2.757e-12 | 2.851e-10 |
46 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 13 | 541 | 3.082e-12 | 3.051e-10 |
47 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 13 | 541 | 3.082e-12 | 3.051e-10 |
48 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 13 | 552 | 3.97e-12 | 3.848e-10 |
49 | REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 8 | 97 | 4.82e-12 | 4.577e-10 |
50 | REGULATION OF CELL DEATH | 18 | 1472 | 4.92e-12 | 4.579e-10 |
51 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 16 | 1079 | 7.099e-12 | 6.477e-10 |
52 | NEGATIVE REGULATION OF CELL GROWTH | 9 | 170 | 1.093e-11 | 9.783e-10 |
53 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 11 | 351 | 1.192e-11 | 1.046e-09 |
54 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 470 | 1.261e-11 | 1.087e-09 |
55 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 11 | 360 | 1.565e-11 | 1.324e-09 |
56 | MITOTIC NUCLEAR DIVISION | 11 | 361 | 1.612e-11 | 1.34e-09 |
57 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 6 | 34 | 2.374e-11 | 1.904e-09 |
58 | ORGANELLE FISSION | 12 | 496 | 2.357e-11 | 1.904e-09 |
59 | CELL DEATH | 15 | 1001 | 3.535e-11 | 2.788e-09 |
60 | REGULATION OF CELL GROWTH | 11 | 391 | 3.797e-11 | 2.945e-09 |
61 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 14 | 829 | 4.088e-11 | 3.118e-09 |
62 | SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 8 | 127 | 4.312e-11 | 3.236e-09 |
63 | POSITIVE REGULATION OF GENE EXPRESSION | 18 | 1733 | 7.524e-11 | 5.557e-09 |
64 | NEGATIVE REGULATION OF PHOSPHORYLATION | 11 | 422 | 8.58e-11 | 6.238e-09 |
65 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 17 | 1517 | 1.014e-10 | 7.26e-09 |
66 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 18 | 1805 | 1.475e-10 | 1.026e-08 |
67 | DIGESTIVE SYSTEM DEVELOPMENT | 8 | 148 | 1.477e-10 | 1.026e-08 |
68 | NEGATIVE REGULATION OF GROWTH | 9 | 236 | 2.059e-10 | 1.409e-08 |
69 | REGULATION OF DNA METABOLIC PROCESS | 10 | 340 | 2.225e-10 | 1.5e-08 |
70 | REGULATION OF PROTEIN LOCALIZATION | 14 | 950 | 2.468e-10 | 1.641e-08 |
71 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 15 | 1152 | 2.542e-10 | 1.666e-08 |
72 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 6 | 50 | 2.749e-10 | 1.777e-08 |
73 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 12 | 616 | 2.861e-10 | 1.823e-08 |
74 | REGULATION OF INTRACELLULAR TRANSPORT | 12 | 621 | 3.138e-10 | 1.973e-08 |
75 | POSITIVE REGULATION OF KINASE ACTIVITY | 11 | 482 | 3.52e-10 | 2.184e-08 |
76 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 10 | 370 | 5.061e-10 | 3.098e-08 |
77 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 11 | 514 | 6.937e-10 | 4.192e-08 |
78 | REGULATION OF CELL DIFFERENTIATION | 16 | 1492 | 8.843e-10 | 5.275e-08 |
79 | GLAND DEVELOPMENT | 10 | 395 | 9.529e-10 | 5.613e-08 |
80 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 9 | 285 | 1.09e-09 | 6.341e-08 |
81 | APOPTOTIC SIGNALING PATHWAY | 9 | 289 | 1.232e-09 | 7.079e-08 |
82 | RESPONSE TO LIPID | 13 | 888 | 1.422e-09 | 8.067e-08 |
83 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 12 | 720 | 1.686e-09 | 9.363e-08 |
84 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 6 | 67 | 1.69e-09 | 9.363e-08 |
85 | INTRACELLULAR SIGNAL TRANSDUCTION | 16 | 1572 | 1.897e-09 | 1.038e-07 |
86 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 13 | 917 | 2.099e-09 | 1.136e-07 |
87 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 11 | 573 | 2.169e-09 | 1.16e-07 |
88 | RESPONSE TO DRUG | 10 | 431 | 2.208e-09 | 1.168e-07 |
89 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 129 | 2.281e-09 | 1.192e-07 |
90 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 6 | 71 | 2.414e-09 | 1.248e-07 |
91 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 8 | 218 | 3.202e-09 | 1.637e-07 |
92 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 8 | 220 | 3.441e-09 | 1.74e-07 |
93 | CELL CYCLE G2 M PHASE TRANSITION | 7 | 138 | 3.656e-09 | 1.829e-07 |
94 | REPLICATIVE SENESCENCE | 4 | 12 | 3.85e-09 | 1.906e-07 |
95 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 17 | 1929 | 4.204e-09 | 2.059e-07 |
96 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 5 | 36 | 4.417e-09 | 2.141e-07 |
97 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 16 | 1672 | 4.643e-09 | 2.227e-07 |
98 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 9 | 337 | 4.726e-09 | 2.244e-07 |
99 | REGULATION OF FIBROBLAST PROLIFERATION | 6 | 81 | 5.402e-09 | 2.539e-07 |
100 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 12 | 801 | 5.599e-09 | 2.605e-07 |
101 | REGULATION OF GROWTH | 11 | 633 | 6.119e-09 | 2.791e-07 |
102 | RESPONSE TO ENDOGENOUS STIMULUS | 15 | 1450 | 6.075e-09 | 2.791e-07 |
103 | RESPONSE TO STEROID HORMONE | 10 | 497 | 8.625e-09 | 3.896e-07 |
104 | NEGATIVE REGULATION OF GENE EXPRESSION | 15 | 1493 | 9.04e-09 | 4.045e-07 |
105 | NEGATIVE REGULATION OF KINASE ACTIVITY | 8 | 250 | 9.371e-09 | 4.153e-07 |
106 | REGULATION OF DNA REPLICATION | 7 | 161 | 1.069e-08 | 4.694e-07 |
107 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 15 | 1518 | 1.132e-08 | 4.852e-07 |
108 | REGULATION OF CELLULAR LOCALIZATION | 14 | 1277 | 1.137e-08 | 4.852e-07 |
109 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 162 | 1.116e-08 | 4.852e-07 |
110 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 16 | 1791 | 1.249e-08 | 5.284e-07 |
111 | POSITIVE REGULATION OF CELL COMMUNICATION | 15 | 1532 | 1.282e-08 | 5.375e-07 |
112 | REGULATION OF CELL DIVISION | 8 | 272 | 1.808e-08 | 7.512e-07 |
113 | REGULATION OF BINDING | 8 | 283 | 2.46e-08 | 1.013e-06 |
114 | RESPONSE TO RADIATION | 9 | 413 | 2.747e-08 | 1.121e-06 |
115 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 13 | 1142 | 2.911e-08 | 1.178e-06 |
116 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 11 | 740 | 3.06e-08 | 1.228e-06 |
117 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 5 | 53 | 3.291e-08 | 1.309e-06 |
118 | NEGATIVE REGULATION OF DNA METABOLIC PROCESS | 6 | 111 | 3.631e-08 | 1.432e-06 |
119 | NEUROGENESIS | 14 | 1402 | 3.714e-08 | 1.452e-06 |
120 | IMMUNE SYSTEM DEVELOPMENT | 10 | 582 | 3.841e-08 | 1.489e-06 |
121 | NEGATIVE REGULATION OF DNA REPLICATION | 5 | 55 | 3.98e-08 | 1.531e-06 |
122 | REGULATION OF STEM CELL DIFFERENTIATION | 6 | 113 | 4.041e-08 | 1.541e-06 |
123 | SMAD PROTEIN SIGNAL TRANSDUCTION | 5 | 56 | 4.365e-08 | 1.651e-06 |
124 | NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 6 | 115 | 4.489e-08 | 1.685e-06 |
125 | CELL DEVELOPMENT | 14 | 1426 | 4.599e-08 | 1.712e-06 |
126 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 10 | 609 | 5.878e-08 | 2.171e-06 |
127 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 7 | 207 | 6.045e-08 | 2.212e-06 |
128 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 6.086e-08 | 2.212e-06 |
129 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 4 | 23 | 6.795e-08 | 2.432e-06 |
130 | POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 4 | 23 | 6.795e-08 | 2.432e-06 |
131 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 12 | 1004 | 6.847e-08 | 2.432e-06 |
132 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 12 | 1008 | 7.152e-08 | 2.521e-06 |
133 | CHROMOSOME ORGANIZATION | 12 | 1009 | 7.23e-08 | 2.53e-06 |
134 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 7.751e-08 | 2.691e-06 |
135 | RESPONSE TO GROWTH FACTOR | 9 | 475 | 9.091e-08 | 3.133e-06 |
136 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 1784 | 9.857e-08 | 3.372e-06 |
137 | REGULATION OF CYTOPLASMIC TRANSPORT | 9 | 481 | 1.012e-07 | 3.436e-06 |
138 | CELLULAR RESPONSE TO RADIATION | 6 | 137 | 1.276e-07 | 4.302e-06 |
139 | REPRODUCTION | 13 | 1297 | 1.299e-07 | 4.35e-06 |
140 | CELLULAR RESPONSE TO STRESS | 14 | 1565 | 1.471e-07 | 4.887e-06 |
141 | NEGATIVE REGULATION OF CELL DEATH | 11 | 872 | 1.621e-07 | 5.349e-06 |
142 | POSITIVE REGULATION OF PROTEOLYSIS | 8 | 363 | 1.673e-07 | 5.481e-06 |
143 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 6 | 144 | 1.715e-07 | 5.58e-06 |
144 | RESPONSE TO IONIZING RADIATION | 6 | 145 | 1.787e-07 | 5.687e-06 |
145 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 1.809e-07 | 5.687e-06 |
146 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 1.809e-07 | 5.687e-06 |
147 | REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 4 | 29 | 1.809e-07 | 5.687e-06 |
148 | REGULATION OF HEART MORPHOGENESIS | 4 | 29 | 1.809e-07 | 5.687e-06 |
149 | POSITIVE REGULATION OF CHROMOSOME ORGANIZATION | 6 | 150 | 2.184e-07 | 6.819e-06 |
150 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 152 | 2.362e-07 | 7.326e-06 |
151 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 381 | 2.419e-07 | 7.455e-06 |
152 | REGULATION OF PROTEOLYSIS | 10 | 711 | 2.482e-07 | 7.599e-06 |
153 | AGING | 7 | 264 | 3.162e-07 | 9.617e-06 |
154 | TUBE DEVELOPMENT | 9 | 552 | 3.241e-07 | 9.728e-06 |
155 | REGULATION OF CELL MORPHOGENESIS | 9 | 552 | 3.241e-07 | 9.728e-06 |
156 | POSITIVE REGULATION OF TRANSPORT | 11 | 936 | 3.299e-07 | 9.839e-06 |
157 | REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 6 | 162 | 3.44e-07 | 1.019e-05 |
158 | EPITHELIUM DEVELOPMENT | 11 | 945 | 3.629e-07 | 1.062e-05 |
159 | POSITIVE REGULATION OF CHROMATIN MODIFICATION | 5 | 85 | 3.615e-07 | 1.062e-05 |
160 | GROWTH | 8 | 410 | 4.222e-07 | 1.228e-05 |
161 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 36 | 4.448e-07 | 1.285e-05 |
162 | REGULATION OF CHROMOSOME ORGANIZATION | 7 | 278 | 4.481e-07 | 1.287e-05 |
163 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 6 | 171 | 4.728e-07 | 1.35e-05 |
164 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 7 | 282 | 4.933e-07 | 1.4e-05 |
165 | REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 4 | 38 | 5.56e-07 | 1.568e-05 |
166 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 7 | 289 | 5.817e-07 | 1.631e-05 |
167 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 5 | 95 | 6.305e-07 | 1.757e-05 |
168 | RESPONSE TO KETONE | 6 | 182 | 6.816e-07 | 1.888e-05 |
169 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 7.039e-07 | 1.938e-05 |
170 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 5 | 99 | 7.745e-07 | 2.095e-05 |
171 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 5 | 99 | 7.745e-07 | 2.095e-05 |
172 | MEIOTIC CELL CYCLE | 6 | 186 | 7.741e-07 | 2.095e-05 |
173 | POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 5 | 100 | 8.142e-07 | 2.19e-05 |
174 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 8.722e-07 | 2.332e-05 |
175 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 43 | 9.238e-07 | 2.456e-05 |
176 | POSITIVE REGULATION OF PROTEIN IMPORT | 5 | 104 | 9.896e-07 | 2.616e-05 |
177 | REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 3 | 12 | 1.068e-06 | 2.793e-05 |
178 | POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 3 | 12 | 1.068e-06 | 2.793e-05 |
179 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 8 | 465 | 1.09e-06 | 2.827e-05 |
180 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 1.094e-06 | 2.827e-05 |
181 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 14 | 1848 | 1.128e-06 | 2.899e-05 |
182 | PEPTIDYL AMINO ACID MODIFICATION | 10 | 841 | 1.154e-06 | 2.951e-05 |
183 | SISTER CHROMATID COHESION | 5 | 111 | 1.367e-06 | 3.476e-05 |
184 | MITOTIC CELL CYCLE ARREST | 3 | 13 | 1.387e-06 | 3.508e-05 |
185 | POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 4 | 48 | 1.447e-06 | 3.641e-05 |
186 | NOTCH SIGNALING PATHWAY | 5 | 114 | 1.56e-06 | 3.903e-05 |
187 | PROTEIN SUMOYLATION | 5 | 115 | 1.629e-06 | 4.053e-05 |
188 | SENSORY ORGAN DEVELOPMENT | 8 | 493 | 1.688e-06 | 4.177e-05 |
189 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 213 | 1.706e-06 | 4.199e-05 |
190 | LYMPHOCYTE ACTIVATION | 7 | 342 | 1.791e-06 | 4.386e-05 |
191 | RESPONSE TO ESTROGEN | 6 | 218 | 1.951e-06 | 4.754e-05 |
192 | RESPONSE TO HORMONE | 10 | 893 | 1.985e-06 | 4.811e-05 |
193 | CELLULAR RESPONSE TO IONIZING RADIATION | 4 | 52 | 2.004e-06 | 4.831e-05 |
194 | REGULATION OF CELLULAR RESPONSE TO STRESS | 9 | 691 | 2.099e-06 | 5.035e-05 |
195 | INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 4 | 53 | 2.165e-06 | 5.166e-05 |
196 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 5 | 123 | 2.27e-06 | 5.39e-05 |
197 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 1395 | 2.336e-06 | 5.516e-05 |
198 | REGULATION OF IMMUNE SYSTEM PROCESS | 12 | 1403 | 2.48e-06 | 5.827e-05 |
199 | NUCLEAR CHROMOSOME SEGREGATION | 6 | 228 | 2.53e-06 | 5.916e-05 |
200 | RESPONSE TO UV | 5 | 126 | 2.557e-06 | 5.948e-05 |
201 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 6 | 229 | 2.595e-06 | 5.977e-05 |
202 | HEAD DEVELOPMENT | 9 | 709 | 2.593e-06 | 5.977e-05 |
203 | RESPONSE TO ALCOHOL | 7 | 362 | 2.61e-06 | 5.983e-05 |
204 | REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 3 | 16 | 2.707e-06 | 6.174e-05 |
205 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 5 | 128 | 2.763e-06 | 6.27e-05 |
206 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 7 | 372 | 3.125e-06 | 7.058e-05 |
207 | POSITIVE REGULATION OF CELL DIVISION | 5 | 132 | 3.214e-06 | 7.224e-05 |
208 | POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 3 | 17 | 3.283e-06 | 7.309e-05 |
209 | PROTEIN PHOSPHORYLATION | 10 | 944 | 3.267e-06 | 7.309e-05 |
210 | REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 4 | 59 | 3.34e-06 | 7.365e-05 |
211 | REGULATION OF CATABOLIC PROCESS | 9 | 731 | 3.33e-06 | 7.365e-05 |
212 | REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 4 | 60 | 3.574e-06 | 7.807e-05 |
213 | REGULATION OF ORGAN MORPHOGENESIS | 6 | 242 | 3.569e-06 | 7.807e-05 |
214 | SOMITOGENESIS | 4 | 62 | 4.078e-06 | 8.868e-05 |
215 | REGULATION OF PROTEIN CATABOLIC PROCESS | 7 | 393 | 4.485e-06 | 9.707e-05 |
216 | REGULATION OF CYTOKINE PRODUCTION | 8 | 563 | 4.514e-06 | 9.724e-05 |
217 | REGULATION OF PROTEIN ACETYLATION | 4 | 64 | 4.634e-06 | 9.936e-05 |
218 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 10 | 983 | 4.687e-06 | 1e-04 |
219 | RAS PROTEIN SIGNAL TRANSDUCTION | 5 | 143 | 4.758e-06 | 0.0001011 |
220 | CELL ACTIVATION | 8 | 568 | 4.818e-06 | 0.0001019 |
221 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 9 | 767 | 4.928e-06 | 0.0001037 |
222 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 6 | 258 | 5.157e-06 | 0.0001081 |
223 | CELLULAR RESPONSE TO UV | 4 | 66 | 5.243e-06 | 0.0001094 |
224 | POSITIVE REGULATION OF NEURON DEATH | 4 | 67 | 5.569e-06 | 0.0001142 |
225 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 7 | 406 | 5.553e-06 | 0.0001142 |
226 | CELL AGING | 4 | 67 | 5.569e-06 | 0.0001142 |
227 | REGULATION OF TRANSPORT | 13 | 1804 | 5.544e-06 | 0.0001142 |
228 | TISSUE DEVELOPMENT | 12 | 1518 | 5.627e-06 | 0.0001148 |
229 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 6 | 263 | 5.756e-06 | 0.000117 |
230 | LEUKOCYTE ACTIVATION | 7 | 414 | 6.309e-06 | 0.0001276 |
231 | REGULATION OF CHROMATIN ORGANIZATION | 5 | 152 | 6.411e-06 | 0.0001286 |
232 | MEIOTIC CELL CYCLE PROCESS | 5 | 152 | 6.411e-06 | 0.0001286 |
233 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 10 | 1021 | 6.56e-06 | 0.000131 |
234 | REGULATION OF MEMBRANE PERMEABILITY | 4 | 70 | 6.637e-06 | 0.000132 |
235 | CHROMOSOME SEGREGATION | 6 | 272 | 6.979e-06 | 0.0001382 |
236 | NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 22 | 7.39e-06 | 0.0001457 |
237 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 9 | 823 | 8.715e-06 | 0.0001711 |
238 | SOMITE DEVELOPMENT | 4 | 78 | 1.022e-05 | 0.0001999 |
239 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 3 | 25 | 1.1e-05 | 0.0002141 |
240 | RHYTHMIC PROCESS | 6 | 298 | 1.174e-05 | 0.0002276 |
241 | CELLULAR RESPONSE TO LIPID | 7 | 457 | 1.2e-05 | 0.0002318 |
242 | REGULATION OF CELLULAR SENESCENCE | 3 | 26 | 1.242e-05 | 0.0002387 |
243 | GLIOGENESIS | 5 | 175 | 1.271e-05 | 0.0002434 |
244 | ORGAN REGENERATION | 4 | 83 | 1.309e-05 | 0.0002486 |
245 | SISTER CHROMATID SEGREGATION | 5 | 176 | 1.307e-05 | 0.0002486 |
246 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 12 | 1656 | 1.372e-05 | 0.0002586 |
247 | POSITIVE REGULATION OF OSSIFICATION | 4 | 84 | 1.373e-05 | 0.0002586 |
248 | REGULATION OF OSSIFICATION | 5 | 178 | 1.38e-05 | 0.0002589 |
249 | REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 3 | 27 | 1.395e-05 | 0.0002607 |
250 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 9 | 876 | 1.438e-05 | 0.0002676 |
251 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 11 | 1381 | 1.453e-05 | 0.0002694 |
252 | POSITIVE REGULATION OF CELL DEVELOPMENT | 7 | 472 | 1.479e-05 | 0.0002732 |
253 | CHROMATIN ORGANIZATION | 8 | 663 | 1.489e-05 | 0.0002738 |
254 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 86 | 1.507e-05 | 0.0002761 |
255 | PEPTIDYL LYSINE MODIFICATION | 6 | 312 | 1.523e-05 | 0.0002779 |
256 | POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 3 | 28 | 1.561e-05 | 0.0002837 |
257 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 5 | 184 | 1.62e-05 | 0.0002932 |
258 | DNA REPAIR | 7 | 480 | 1.649e-05 | 0.0002974 |
259 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 5 | 185 | 1.663e-05 | 0.0002987 |
260 | EMBRYO DEVELOPMENT | 9 | 894 | 1.691e-05 | 0.0003026 |
261 | SEGMENTATION | 4 | 89 | 1.726e-05 | 0.0003078 |
262 | NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 3 | 29 | 1.739e-05 | 0.0003088 |
263 | MESONEPHROS DEVELOPMENT | 4 | 90 | 1.804e-05 | 0.0003192 |
264 | CELLULAR RESPONSE TO LIGHT STIMULUS | 4 | 91 | 1.885e-05 | 0.000332 |
265 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 5 | 190 | 1.891e-05 | 0.000332 |
266 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR | 3 | 30 | 1.93e-05 | 0.0003363 |
267 | RESPONSE TO X RAY | 3 | 30 | 1.93e-05 | 0.0003363 |
268 | EYE DEVELOPMENT | 6 | 326 | 1.951e-05 | 0.0003388 |
269 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 4 | 92 | 1.968e-05 | 0.0003404 |
270 | DEVELOPMENTAL MATURATION | 5 | 193 | 2.039e-05 | 0.0003513 |
271 | REGULATION OF DNA BINDING | 4 | 93 | 2.054e-05 | 0.0003527 |
272 | REGULATION OF DNA BIOSYNTHETIC PROCESS | 4 | 94 | 2.143e-05 | 0.0003665 |
273 | REGULATION OF CYTOSKELETON ORGANIZATION | 7 | 502 | 2.2e-05 | 0.0003736 |
274 | DEVELOPMENTAL GROWTH | 6 | 333 | 2.2e-05 | 0.0003736 |
275 | NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 32 | 2.352e-05 | 0.0003965 |
276 | SALIVARY GLAND DEVELOPMENT | 3 | 32 | 2.352e-05 | 0.0003965 |
277 | CELLULAR SENESCENCE | 3 | 33 | 2.584e-05 | 0.0004309 |
278 | REGULATION OF RESPONSE TO STRESS | 11 | 1468 | 2.578e-05 | 0.0004309 |
279 | REGULATION OF CELL AGING | 3 | 33 | 2.584e-05 | 0.0004309 |
280 | REGULATION OF PROTEIN DEACETYLATION | 3 | 34 | 2.831e-05 | 0.0004704 |
281 | NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 4 | 102 | 2.956e-05 | 0.0004896 |
282 | LYMPHOCYTE DIFFERENTIATION | 5 | 209 | 2.988e-05 | 0.000493 |
283 | RESPONSE TO MINERALOCORTICOID | 3 | 35 | 3.092e-05 | 0.0005084 |
284 | POSITIVE REGULATION OF PROTEIN SECRETION | 5 | 211 | 3.127e-05 | 0.0005123 |
285 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 104 | 3.191e-05 | 0.000521 |
286 | PHOSPHORYLATION | 10 | 1228 | 3.277e-05 | 0.0005331 |
287 | POSITIVE REGULATION OF PROTEIN ACETYLATION | 3 | 36 | 3.369e-05 | 0.0005443 |
288 | HEAD MORPHOGENESIS | 3 | 36 | 3.369e-05 | 0.0005443 |
289 | CHROMATIN MODIFICATION | 7 | 539 | 3.467e-05 | 0.0005582 |
290 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 6 | 363 | 3.568e-05 | 0.0005725 |
291 | REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 218 | 3.655e-05 | 0.0005844 |
292 | NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 4 | 109 | 3.837e-05 | 0.0006114 |
293 | POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 3 | 38 | 3.971e-05 | 0.0006264 |
294 | MESENCHYME MORPHOGENESIS | 3 | 38 | 3.971e-05 | 0.0006264 |
295 | POSITIVE REGULATION OF SECRETION | 6 | 370 | 3.97e-05 | 0.0006264 |
296 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 7 | 554 | 4.128e-05 | 0.0006489 |
297 | MULTICELLULAR ORGANISM REPRODUCTION | 8 | 768 | 4.268e-05 | 0.0006687 |
298 | REGULATION OF DNA DEPENDENT DNA REPLICATION | 3 | 41 | 5e-05 | 0.0007781 |
299 | NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION | 3 | 41 | 5e-05 | 0.0007781 |
300 | REGULATION OF PEPTIDASE ACTIVITY | 6 | 392 | 5.474e-05 | 0.000849 |
301 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 4 | 121 | 5.773e-05 | 0.0008894 |
302 | REGULATION OF B CELL ACTIVATION | 4 | 121 | 5.773e-05 | 0.0008894 |
303 | RESPONSE TO TOXIC SUBSTANCE | 5 | 241 | 5.89e-05 | 0.0009044 |
304 | BODY MORPHOGENESIS | 3 | 44 | 6.19e-05 | 0.0009474 |
305 | KIDNEY EPITHELIUM DEVELOPMENT | 4 | 125 | 6.553e-05 | 0.0009997 |
306 | EXOCRINE SYSTEM DEVELOPMENT | 3 | 45 | 6.624e-05 | 0.001007 |
307 | POSITIVE REGULATION OF BINDING | 4 | 127 | 6.971e-05 | 0.001056 |
308 | REGULATION OF NEURON DEATH | 5 | 252 | 7.275e-05 | 0.001099 |
309 | RESPONSE TO ANTIBIOTIC | 3 | 47 | 7.551e-05 | 0.001133 |
310 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 3 | 47 | 7.551e-05 | 0.001133 |
311 | REGULATION OF LIGASE ACTIVITY | 4 | 130 | 7.633e-05 | 0.001142 |
312 | LEUKOCYTE CELL CELL ADHESION | 5 | 255 | 7.693e-05 | 0.001147 |
313 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 10 | 1360 | 7.801e-05 | 0.00116 |
314 | CELL MATURATION | 4 | 131 | 7.864e-05 | 0.001162 |
315 | PROTEIN STABILIZATION | 4 | 131 | 7.864e-05 | 0.001162 |
316 | ORGAN MORPHOGENESIS | 8 | 841 | 8.093e-05 | 0.001192 |
317 | CELL GROWTH | 4 | 135 | 8.837e-05 | 0.001297 |
318 | RESPONSE TO ETHANOL | 4 | 136 | 9.094e-05 | 0.00131 |
319 | LYMPHOCYTE HOMEOSTASIS | 3 | 50 | 9.095e-05 | 0.00131 |
320 | FACE DEVELOPMENT | 3 | 50 | 9.095e-05 | 0.00131 |
321 | RESPONSE TO PROGESTERONE | 3 | 50 | 9.095e-05 | 0.00131 |
322 | RESPONSE TO GAMMA RADIATION | 3 | 50 | 9.095e-05 | 0.00131 |
323 | GLIAL CELL DIFFERENTIATION | 4 | 136 | 9.094e-05 | 0.00131 |
324 | RESPONSE TO NITROGEN COMPOUND | 8 | 859 | 9.384e-05 | 0.001348 |
325 | NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 4 | 139 | 9.896e-05 | 0.001417 |
326 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 8 | 872 | 0.0001042 | 0.001487 |
327 | REGULATION OF HOMEOSTATIC PROCESS | 6 | 447 | 0.0001129 | 0.001606 |
328 | REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS | 4 | 145 | 0.0001165 | 0.001653 |
329 | RESPONSE TO ESTRADIOL | 4 | 146 | 0.0001197 | 0.001687 |
330 | RESPONSE TO LIGHT STIMULUS | 5 | 280 | 0.0001194 | 0.001687 |
331 | CRANIAL SKELETAL SYSTEM DEVELOPMENT | 3 | 55 | 0.000121 | 0.001696 |
332 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.000121 | 0.001696 |
333 | SKELETAL SYSTEM DEVELOPMENT | 6 | 455 | 0.0001244 | 0.001738 |
334 | EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 56 | 0.0001277 | 0.001779 |
335 | CHROMATIN REMODELING | 4 | 150 | 0.0001328 | 0.001845 |
336 | REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 57 | 0.0001346 | 0.001865 |
337 | CELL PROLIFERATION | 7 | 672 | 0.0001387 | 0.001914 |
338 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 152 | 0.0001398 | 0.001924 |
339 | LEUKOCYTE DIFFERENTIATION | 5 | 292 | 0.0001453 | 0.001995 |
340 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 4 | 154 | 0.000147 | 0.002011 |
341 | LEUKOCYTE HOMEOSTASIS | 3 | 60 | 0.0001569 | 0.002141 |
342 | NEURON DEVELOPMENT | 7 | 687 | 0.0001589 | 0.002156 |
343 | NEGATIVE REGULATION OF CELL COMMUNICATION | 9 | 1192 | 0.0001586 | 0.002156 |
344 | REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY | 2 | 11 | 0.000162 | 0.002176 |
345 | REGULATION OF DEPHOSPHORYLATION | 4 | 158 | 0.0001622 | 0.002176 |
346 | NEGATIVE REGULATION OF CELLULAR SENESCENCE | 2 | 11 | 0.000162 | 0.002176 |
347 | UROGENITAL SYSTEM DEVELOPMENT | 5 | 299 | 0.0001623 | 0.002176 |
348 | MEMBRANE DEPOLARIZATION | 3 | 61 | 0.0001648 | 0.002191 |
349 | RESPONSE TO INORGANIC SUBSTANCE | 6 | 479 | 0.0001646 | 0.002191 |
350 | CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 3 | 61 | 0.0001648 | 0.002191 |
351 | REGENERATION | 4 | 161 | 0.0001744 | 0.002311 |
352 | POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 4 | 162 | 0.0001786 | 0.00236 |
353 | REGULATION OF CARTILAGE DEVELOPMENT | 3 | 63 | 0.0001814 | 0.002391 |
354 | REGULATION OF NUCLEAR DIVISION | 4 | 163 | 0.0001828 | 0.002403 |
355 | RESPONSE TO EXTERNAL STIMULUS | 11 | 1821 | 0.0001838 | 0.002409 |
356 | POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS | 3 | 64 | 0.0001901 | 0.002485 |
357 | MITOTIC SISTER CHROMATID COHESION | 2 | 12 | 0.0001942 | 0.002531 |
358 | IN UTERO EMBRYONIC DEVELOPMENT | 5 | 311 | 0.0001949 | 0.002533 |
359 | EPITHELIAL CELL DIFFERENTIATION | 6 | 495 | 0.0001966 | 0.002549 |
360 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 5 | 312 | 0.0001978 | 0.002557 |
361 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 4 | 167 | 0.0002006 | 0.002586 |
362 | REGULATION OF HEMOPOIESIS | 5 | 314 | 0.0002038 | 0.002619 |
363 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 3 | 66 | 0.0002083 | 0.002656 |
364 | NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 3 | 66 | 0.0002083 | 0.002656 |
365 | LENS DEVELOPMENT IN CAMERA TYPE EYE | 3 | 66 | 0.0002083 | 0.002656 |
366 | CELLULAR RESPONSE TO DRUG | 3 | 67 | 0.0002178 | 0.002769 |
367 | POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 3 | 68 | 0.0002276 | 0.002886 |
368 | POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 2 | 13 | 0.0002293 | 0.002891 |
369 | PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 2 | 13 | 0.0002293 | 0.002891 |
370 | NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION | 3 | 69 | 0.0002377 | 0.002981 |
371 | NEGATIVE REGULATION OF OSSIFICATION | 3 | 69 | 0.0002377 | 0.002981 |
372 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 6 | 513 | 0.0002385 | 0.002983 |
373 | HOMEOSTASIS OF NUMBER OF CELLS | 4 | 175 | 0.0002399 | 0.002993 |
374 | RESPONSE TO CORTICOSTEROID | 4 | 176 | 0.0002452 | 0.003051 |
375 | MITOCHONDRIAL TRANSPORT | 4 | 177 | 0.0002506 | 0.003109 |
376 | ENDODERM DEVELOPMENT | 3 | 71 | 0.0002586 | 0.003201 |
377 | POSITIVE REGULATION OF HISTONE DEACETYLATION | 2 | 14 | 0.0002672 | 0.003263 |
378 | DETERMINATION OF ADULT LIFESPAN | 2 | 14 | 0.0002672 | 0.003263 |
379 | CRANIOFACIAL SUTURE MORPHOGENESIS | 2 | 14 | 0.0002672 | 0.003263 |
380 | REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY | 2 | 14 | 0.0002672 | 0.003263 |
381 | RESPONSE TO LAMINAR FLUID SHEAR STRESS | 2 | 14 | 0.0002672 | 0.003263 |
382 | DNA METABOLIC PROCESS | 7 | 758 | 0.0002904 | 0.003538 |
383 | CELL JUNCTION ORGANIZATION | 4 | 185 | 0.0002965 | 0.003602 |
384 | REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 3 | 75 | 0.0003041 | 0.003685 |
385 | REGULATION OF HAIR FOLLICLE DEVELOPMENT | 2 | 15 | 0.000308 | 0.003703 |
386 | NEGATIVE REGULATION OF B CELL PROLIFERATION | 2 | 15 | 0.000308 | 0.003703 |
387 | POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS | 2 | 15 | 0.000308 | 0.003703 |
388 | REGULATION OF CELLULAR RESPONSE TO HEAT | 3 | 76 | 0.0003162 | 0.003792 |
389 | MYELOID CELL DIFFERENTIATION | 4 | 189 | 0.0003216 | 0.003847 |
390 | MESENCHYME DEVELOPMENT | 4 | 190 | 0.0003282 | 0.003905 |
391 | STEM CELL DIFFERENTIATION | 4 | 190 | 0.0003282 | 0.003905 |
392 | NEURON PROJECTION DEVELOPMENT | 6 | 545 | 0.0003299 | 0.003916 |
393 | RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 191 | 0.0003348 | 0.003963 |
394 | REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 192 | 0.0003415 | 0.004033 |
395 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 5 | 352 | 0.0003452 | 0.004056 |
396 | RESPONSE TO OXIDATIVE STRESS | 5 | 352 | 0.0003452 | 0.004056 |
397 | NEGATIVE REGULATION OF DNA DEPENDENT DNA REPLICATION | 2 | 16 | 0.0003516 | 0.00411 |
398 | CELLULAR RESPONSE TO ANTIBIOTIC | 2 | 16 | 0.0003516 | 0.00411 |
399 | REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 3 | 79 | 0.0003544 | 0.004121 |
400 | REGULATION OF HYDROLASE ACTIVITY | 9 | 1327 | 0.0003543 | 0.004121 |
401 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 4 | 194 | 0.0003551 | 0.004121 |
402 | REGULATION OF CELL PROJECTION ORGANIZATION | 6 | 558 | 0.0003741 | 0.004331 |
403 | IMMUNE SYSTEM PROCESS | 11 | 1984 | 0.0003902 | 0.004505 |
404 | NEGATIVE REGULATION OF CELL AGING | 2 | 17 | 0.000398 | 0.004573 |
405 | POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 2 | 17 | 0.000398 | 0.004573 |
406 | SKELETAL SYSTEM MORPHOGENESIS | 4 | 201 | 0.0004062 | 0.004655 |
407 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 5 | 365 | 0.0004075 | 0.004659 |
408 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 4 | 203 | 0.0004216 | 0.004809 |
409 | POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 3 | 84 | 0.0004245 | 0.004829 |
410 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 5 | 370 | 0.0004337 | 0.004922 |
411 | REGULATION OF LEUKOCYTE PROLIFERATION | 4 | 206 | 0.0004457 | 0.005039 |
412 | POSITIVE REGULATION OF PROTEIN DEACETYLATION | 2 | 18 | 0.0004473 | 0.005039 |
413 | UTERUS DEVELOPMENT | 2 | 18 | 0.0004473 | 0.005039 |
414 | POSITIVE REGULATION OF DNA REPLICATION | 3 | 86 | 0.0004548 | 0.005112 |
415 | REGULATION OF CATION TRANSMEMBRANE TRANSPORT | 4 | 208 | 0.0004622 | 0.005182 |
416 | TISSUE REMODELING | 3 | 87 | 0.0004705 | 0.005263 |
417 | MEIOSIS I | 3 | 88 | 0.0004866 | 0.005403 |
418 | LEUKOCYTE PROLIFERATION | 3 | 88 | 0.0004866 | 0.005403 |
419 | OVULATION CYCLE PROCESS | 3 | 88 | 0.0004866 | 0.005403 |
420 | B CELL DIFFERENTIATION | 3 | 89 | 0.0005029 | 0.005572 |
421 | REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 4 | 213 | 0.0005055 | 0.005587 |
422 | REGULATION OF CELL MATRIX ADHESION | 3 | 90 | 0.0005196 | 0.00573 |
423 | GAMETE GENERATION | 6 | 595 | 0.0005259 | 0.005785 |
424 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 4 | 216 | 0.0005328 | 0.005847 |
425 | REGULATION OF PROTEIN SECRETION | 5 | 389 | 0.0005447 | 0.005963 |
426 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 4 | 218 | 0.0005516 | 0.006025 |
427 | POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 2 | 20 | 0.0005542 | 0.006039 |
428 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 6 | 602 | 0.0005594 | 0.006081 |
429 | REGULATION OF PROTEIN STABILITY | 4 | 221 | 0.0005807 | 0.006298 |
430 | NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 5 | 397 | 0.0005973 | 0.006464 |
431 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 3 | 95 | 0.0006086 | 0.00657 |
432 | REGULATION OF PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION | 2 | 21 | 0.0006119 | 0.00659 |
433 | MORPHOGENESIS OF AN EPITHELIUM | 5 | 400 | 0.000618 | 0.006641 |
434 | GLAND MORPHOGENESIS | 3 | 97 | 0.0006467 | 0.006934 |
435 | HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 3 | 98 | 0.0006664 | 0.007128 |
436 | REGULATION OF HAIR CYCLE | 2 | 22 | 0.0006723 | 0.007142 |
437 | ENDOCARDIAL CUSHION MORPHOGENESIS | 2 | 22 | 0.0006723 | 0.007142 |
438 | SOMATIC STEM CELL DIVISION | 2 | 22 | 0.0006723 | 0.007142 |
439 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 5 | 408 | 0.0006759 | 0.007164 |
440 | NEURON DIFFERENTIATION | 7 | 874 | 0.0006834 | 0.007227 |
441 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 3 | 99 | 0.0006864 | 0.007242 |
442 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 4 | 232 | 0.0006965 | 0.007333 |
443 | REGULATION OF CELL ADHESION | 6 | 629 | 0.0007043 | 0.007398 |
444 | MODIFICATION OF MORPHOLOGY OR PHYSIOLOGY OF OTHER ORGANISM | 3 | 100 | 0.0007067 | 0.007406 |
445 | REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 3 | 101 | 0.0007275 | 0.007607 |
446 | RESPONSE TO INCREASED OXYGEN LEVELS | 2 | 23 | 0.0007355 | 0.007639 |
447 | REGULATION OF OSTEOBLAST PROLIFERATION | 2 | 23 | 0.0007355 | 0.007639 |
448 | RESPONSE TO HYPEROXIA | 2 | 23 | 0.0007355 | 0.007639 |
449 | NEGATIVE REGULATION OF IMMUNE EFFECTOR PROCESS | 3 | 102 | 0.0007486 | 0.007758 |
450 | MULTI ORGANISM REPRODUCTIVE PROCESS | 7 | 891 | 0.0007659 | 0.00792 |
451 | REGULATION OF HISTONE DEACETYLATION | 2 | 24 | 0.0008015 | 0.008197 |
452 | POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 2 | 24 | 0.0008015 | 0.008197 |
453 | POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 2 | 24 | 0.0008015 | 0.008197 |
454 | CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 2 | 24 | 0.0008015 | 0.008197 |
455 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 2 | 24 | 0.0008015 | 0.008197 |
456 | CELLULAR COMPONENT MORPHOGENESIS | 7 | 900 | 0.0008127 | 0.008292 |
457 | ODONTOGENESIS | 3 | 105 | 0.0008144 | 0.008292 |
458 | REGULATION OF FAT CELL DIFFERENTIATION | 3 | 106 | 0.0008372 | 0.008505 |
459 | PLATELET DEGRANULATION | 3 | 107 | 0.0008603 | 0.008721 |
460 | LENS FIBER CELL DIFFERENTIATION | 2 | 25 | 0.0008703 | 0.008746 |
461 | CELLULAR RESPONSE TO TOXIC SUBSTANCE | 2 | 25 | 0.0008703 | 0.008746 |
462 | EPITHELIAL CELL APOPTOTIC PROCESS | 2 | 25 | 0.0008703 | 0.008746 |
463 | HISTONE PHOSPHORYLATION | 2 | 25 | 0.0008703 | 0.008746 |
464 | REGULATION OF MAPK CASCADE | 6 | 660 | 0.0009051 | 0.009077 |
465 | RESPONSE TO HYDROGEN PEROXIDE | 3 | 109 | 0.0009077 | 0.009083 |
466 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 6 | 662 | 0.0009195 | 0.009161 |
467 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 6 | 662 | 0.0009195 | 0.009161 |
468 | RESPONSE TO CORTICOSTERONE | 2 | 26 | 0.0009417 | 0.009363 |
469 | ZYMOGEN ACTIVATION | 3 | 112 | 0.000982 | 0.009742 |
470 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 9 | 1527 | 0.0009846 | 0.009748 |
471 | OVULATION CYCLE | 3 | 113 | 0.001008 | 0.009954 |
472 | NEGATIVE REGULATION OF FIBROBLAST PROLIFERATION | 2 | 27 | 0.001016 | 0.009973 |
473 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER INVOLVED IN CELLULAR RESPONSE TO CHEMICAL STIMULUS | 2 | 27 | 0.001016 | 0.009973 |
474 | CELLULAR RESPONSE TO DEXAMETHASONE STIMULUS | 2 | 27 | 0.001016 | 0.009973 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 5 | 12 | 9.562e-12 | 2.961e-09 |
2 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY | 6 | 28 | 6.699e-12 | 2.961e-09 |
3 | ENZYME BINDING | 19 | 1737 | 6.527e-12 | 2.961e-09 |
4 | KINASE BINDING | 12 | 606 | 2.372e-10 | 4.407e-08 |
5 | PROTEIN COMPLEX BINDING | 14 | 935 | 2.003e-10 | 4.407e-08 |
6 | MACROMOLECULAR COMPLEX BINDING | 16 | 1399 | 3.433e-10 | 5.315e-08 |
7 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 5 | 30 | 1.682e-09 | 2.233e-07 |
8 | CORE PROMOTER BINDING | 7 | 152 | 7.171e-09 | 8.327e-07 |
9 | TRANSCRIPTION FACTOR BINDING | 10 | 524 | 1.426e-08 | 1.471e-06 |
10 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 6 | 104 | 2.454e-08 | 2.28e-06 |
11 | KINASE REGULATOR ACTIVITY | 7 | 186 | 2.9e-08 | 2.449e-06 |
12 | PROTEIN HETERODIMERIZATION ACTIVITY | 9 | 468 | 8.011e-08 | 6.202e-06 |
13 | PROTEIN KINASE ACTIVITY | 10 | 640 | 9.35e-08 | 6.681e-06 |
14 | CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 34 | 3.51e-07 | 2.329e-05 |
15 | KINASE INHIBITOR ACTIVITY | 5 | 89 | 4.551e-07 | 2.819e-05 |
16 | REGULATORY REGION NUCLEIC ACID BINDING | 10 | 818 | 8.974e-07 | 5.211e-05 |
17 | KINASE ACTIVITY | 10 | 842 | 1.167e-06 | 6.377e-05 |
18 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING | 4 | 50 | 1.709e-06 | 8.82e-05 |
19 | PROTEIN DIMERIZATION ACTIVITY | 11 | 1149 | 2.492e-06 | 0.0001219 |
20 | CYCLIN BINDING | 3 | 19 | 4.667e-06 | 0.0002168 |
21 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 10 | 992 | 5.082e-06 | 0.0002248 |
22 | CHROMATIN BINDING | 7 | 435 | 8.713e-06 | 0.0003679 |
23 | NF KAPPAB BINDING | 3 | 30 | 1.93e-05 | 0.0007794 |
24 | RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING | 3 | 36 | 3.369e-05 | 0.001304 |
25 | MOLECULAR FUNCTION REGULATOR | 10 | 1353 | 7.47e-05 | 0.002776 |
26 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 5 | 264 | 9.059e-05 | 0.003237 |
27 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 445 | 0.0001101 | 0.00379 |
28 | ACTIVATING TRANSCRIPTION FACTOR BINDING | 3 | 57 | 0.0001346 | 0.004467 |
29 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 9 | 1199 | 0.0001658 | 0.00531 |
30 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 5 | 315 | 0.0002068 | 0.006198 |
31 | ENZYME REGULATOR ACTIVITY | 8 | 959 | 0.0002009 | 0.006198 |
32 | P53 BINDING | 3 | 67 | 0.0002178 | 0.006323 |
33 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 4 | 172 | 0.0002246 | 0.006323 |
34 | SMAD BINDING | 3 | 72 | 0.0002695 | 0.006956 |
35 | GLUCOCORTICOID RECEPTOR BINDING | 2 | 14 | 0.0002672 | 0.006956 |
36 | LIGASE REGULATOR ACTIVITY | 2 | 14 | 0.0002672 | 0.006956 |
37 | CHROMATIN DNA BINDING | 3 | 80 | 0.0003678 | 0.009235 |
38 | STEROID HORMONE RECEPTOR BINDING | 3 | 81 | 0.0003815 | 0.009326 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX | 7 | 31 | 6.768e-14 | 3.952e-11 |
2 | CHROMOSOME | 14 | 880 | 9.01e-11 | 2.611e-08 |
3 | PROTEIN KINASE COMPLEX | 7 | 90 | 1.789e-10 | 2.611e-08 |
4 | CHROMATIN | 11 | 441 | 1.371e-10 | 2.611e-08 |
5 | TRANSFERASE COMPLEX | 12 | 703 | 1.287e-09 | 1.503e-07 |
6 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 8 | 237 | 6.171e-09 | 6.006e-07 |
7 | TRANSCRIPTION FACTOR COMPLEX | 8 | 298 | 3.671e-08 | 3.062e-06 |
8 | CATALYTIC COMPLEX | 12 | 1038 | 9.856e-08 | 7.195e-06 |
9 | RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX | 4 | 101 | 2.844e-05 | 0.00167 |
10 | NUCLEAR CHROMOSOME | 7 | 523 | 2.86e-05 | 0.00167 |
11 | MICROTUBULE CYTOSKELETON | 9 | 1068 | 6.834e-05 | 0.003392 |
12 | NUCLEAR TRANSCRIPTION FACTOR COMPLEX | 4 | 127 | 6.971e-05 | 0.003392 |
13 | PLATELET ALPHA GRANULE LUMEN | 3 | 55 | 0.000121 | 0.005436 |
14 | NUCLEAR CHROMATIN | 5 | 291 | 0.000143 | 0.005966 |
15 | CHROMOSOMAL REGION | 5 | 330 | 0.0002565 | 0.009986 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Cell_cycle_hsa04110 | 35 | 124 | 2.736e-80 | 1.423e-78 | |
2 | Cellular_senescence_hsa04218 | 20 | 160 | 9.905e-34 | 2.575e-32 | |
3 | FoxO_signaling_pathway_hsa04068 | 14 | 132 | 3.023e-22 | 5.241e-21 | |
4 | p53_signaling_pathway_hsa04115 | 11 | 68 | 1.174e-19 | 1.526e-18 | |
5 | Hippo_signaling_pathway_hsa04390 | 11 | 154 | 1.398e-15 | 1.454e-14 | |
6 | PI3K_Akt_signaling_pathway_hsa04151 | 11 | 352 | 1.229e-11 | 1.065e-10 | |
7 | TGF_beta_signaling_pathway_hsa04350 | 7 | 84 | 1.092e-10 | 8.114e-10 | |
8 | Wnt_signaling_pathway_hsa04310 | 8 | 146 | 1.324e-10 | 8.609e-10 | |
9 | Oocyte_meiosis_hsa04114 | 6 | 124 | 7.045e-08 | 4.071e-07 | |
10 | Jak_STAT_signaling_pathway_hsa04630 | 6 | 162 | 3.44e-07 | 1.789e-06 | |
11 | MAPK_signaling_pathway_hsa04010 | 7 | 295 | 6.677e-07 | 3.157e-06 | |
12 | ErbB_signaling_pathway_hsa04012 | 4 | 85 | 1.439e-05 | 6.234e-05 | |
13 | Adherens_junction_hsa04520 | 3 | 72 | 0.0002695 | 0.001078 | |
14 | HIF_1_signaling_pathway_hsa04066 | 3 | 100 | 0.0007067 | 0.002625 | |
15 | Apelin_signaling_pathway_hsa04371 | 3 | 137 | 0.001753 | 0.005589 | |
16 | Apoptosis_hsa04210 | 3 | 138 | 0.00179 | 0.005589 | |
17 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 3 | 139 | 0.001827 | 0.005589 | |
18 | Hedgehog_signaling_pathway_hsa04340 | 2 | 47 | 0.003061 | 0.008732 | |
19 | Notch_signaling_pathway_hsa04330 | 2 | 48 | 0.003191 | 0.008732 | |
20 | Focal_adhesion_hsa04510 | 3 | 199 | 0.005024 | 0.01306 | |
21 | Mitophagy_animal_hsa04137 | 2 | 65 | 0.005775 | 0.0143 | |
22 | Cytokine_cytokine_receptor_interaction_hsa04060 | 3 | 270 | 0.01158 | 0.02737 | |
23 | AMPK_signaling_pathway_hsa04152 | 2 | 121 | 0.01896 | 0.04287 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | RP11-166D19.1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p | 18 | CCND2 | Sponge network | -3.855 | 0 | -2.427 | 0 | 0.629 |
2 | MAGI2-AS3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 16 | CCND2 | Sponge network | -2.414 | 0 | -2.427 | 0 | 0.545 |
3 | MIR143HG |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 17 | CCND2 | Sponge network | -4.237 | 0 | -2.427 | 0 | 0.544 |
4 | RP11-284N8.3 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-96-5p | 14 | CCND2 | Sponge network | -1.414 | 0.007 | -2.427 | 0 | 0.514 |
5 | C20orf166-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p | 13 | CCND2 | Sponge network | -6.333 | 0 | -2.427 | 0 | 0.513 |
6 | LINC00702 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-877-5p;hsa-miR-96-5p | 16 | CCND2 | Sponge network | -2.704 | 0 | -2.427 | 0 | 0.509 |
7 | HAND2-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p | 14 | CCND2 | Sponge network | -5.605 | 0 | -2.427 | 0 | 0.497 |
8 | RP11-175K6.1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-96-5p | 13 | CCND2 | Sponge network | -2.386 | 0 | -2.427 | 0 | 0.477 |
9 | RP11-325F22.2 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p | 12 | CCND2 | Sponge network | -1.801 | 0.01297 | -2.427 | 0 | 0.466 |
10 | GAS6-AS2 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p | 12 | CCND2 | Sponge network | -2.655 | 0 | -2.427 | 0 | 0.458 |
11 | VIM-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a | 10 | CCND2 | Sponge network | -1.424 | 0.00627 | -2.427 | 0 | 0.455 |
12 | LINC00861 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-877-5p;hsa-miR-96-5p | 12 | CCND2 | Sponge network | -1.254 | 0.02528 | -2.427 | 0 | 0.446 |
13 | AC093627.8 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-324-3p | 10 | CCND2 | Sponge network | -5.744 | 0 | -2.427 | 0 | 0.445 |
14 | ADAMTS9-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-877-5p;hsa-miR-96-5p | 15 | CCND2 | Sponge network | -7.614 | 0 | -2.427 | 0 | 0.443 |
15 | DNM3OS |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-96-5p | 14 | CCND2 | Sponge network | -2.298 | 1.0E-5 | -2.427 | 0 | 0.44 |
16 | RP11-867G23.10 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-378a-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -5.684 | 0 | -2.427 | 0 | 0.437 |
17 | AP001055.6 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -1.091 | 0.00522 | -2.427 | 0 | 0.434 |
18 | RP11-426C22.5 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p | 13 | CCND2 | Sponge network | -0.559 | 0.08048 | -2.427 | 0 | 0.425 |
19 | PCED1B-AS1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p | 11 | CCND2 | Sponge network | -0.575 | 0.17488 | -2.427 | 0 | 0.418 |
20 | LINC00092 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -3.407 | 1.0E-5 | -2.427 | 0 | 0.417 |
21 | C4A-AS1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p | 13 | CCND2 | Sponge network | -1.76 | 0.00265 | -2.427 | 0 | 0.416 |
22 | AC011526.1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-96-5p | 10 | CCND2 | Sponge network | -1.209 | 1.0E-5 | -2.427 | 0 | 0.413 |
23 | BZRAP1-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 16 | CCND2 | Sponge network | -2.343 | 0 | -2.427 | 0 | 0.412 |
24 | NR2F1-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 16 | CCND2 | Sponge network | -1.881 | 0 | -2.427 | 0 | 0.411 |
25 | LINC00996 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p | 11 | CCND2 | Sponge network | -1.208 | 0.03775 | -2.427 | 0 | 0.406 |
26 | RP11-753H16.3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-335-5p | 10 | CCND2 | Sponge network | -5.702 | 0 | -2.427 | 0 | 0.402 |
27 | RP11-20J15.3 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-877-5p | 12 | CCND2 | Sponge network | -5.104 | 8.0E-5 | -2.427 | 0 | 0.394 |
28 | NR2F1-AS1 |
hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p | 11 | CDK6 | Sponge network | -1.881 | 0 | -0.774 | 0.06479 | 0.393 |
29 | TBX5-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-877-5p | 14 | CCND2 | Sponge network | -2.557 | 2.0E-5 | -2.427 | 0 | 0.387 |
30 | RP11-554A11.4 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -3.989 | 0 | -2.427 | 0 | 0.379 |
31 | RP11-693J15.4 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a | 12 | CCND2 | Sponge network | -3.319 | 0.00281 | -2.427 | 0 | 0.375 |
32 | AC020571.3 |
hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p | 11 | CCND2 | Sponge network | -0.862 | 0.18422 | -2.427 | 0 | 0.371 |
33 | RP11-180N14.1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-96-5p | 12 | CCND2 | Sponge network | -4.46 | 0 | -2.427 | 0 | 0.371 |
34 | MEG3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-96-5p | 16 | CCND2 | Sponge network | -2.367 | 0 | -2.427 | 0 | 0.37 |
35 | RP11-426C22.4 | hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p | 10 | CCND2 | Sponge network | -0.045 | 0.93351 | -2.427 | 0 | 0.367 |
36 | LINC00883 |
hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p | 10 | CDK6 | Sponge network | -0.614 | 0.0511 | -0.774 | 0.06479 | 0.364 |
37 | LINC00702 |
hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p | 11 | CDK6 | Sponge network | -2.704 | 0 | -0.774 | 0.06479 | 0.364 |
38 | AF131217.1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-335-5p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p | 15 | CCND2 | Sponge network | -5.31 | 0 | -2.427 | 0 | 0.363 |
39 | RP4-647J21.1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -0.501 | 0.33476 | -2.427 | 0 | 0.362 |
40 | RP11-367G6.3 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p | 10 | CCND2 | Sponge network | -1.318 | 0.14472 | -2.427 | 0 | 0.36 |
41 | RP1-151F17.2 | hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-877-5p;hsa-miR-96-5p | 10 | CCND2 | Sponge network | -1.606 | 0 | -2.427 | 0 | 0.36 |
42 | RP11-356J5.12 |
hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-501-3p | 10 | CDK6 | Sponge network | -2.015 | 0 | -0.774 | 0.06479 | 0.358 |
43 | RP11-81H14.2 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-96-5p | 13 | CCND2 | Sponge network | -2.322 | 0.00014 | -2.427 | 0 | 0.353 |
44 | PDZRN3-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a | 12 | CCND2 | Sponge network | -5.049 | 1.0E-5 | -2.427 | 0 | 0.353 |
45 | RP11-887P2.5 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p | 10 | CCND2 | Sponge network | -6.751 | 0 | -2.427 | 0 | 0.352 |
46 | FENDRR |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-96-5p | 15 | CCND2 | Sponge network | -4.793 | 0 | -2.427 | 0 | 0.35 |
47 | ACTA2-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-96-5p | 14 | CCND2 | Sponge network | -3.838 | 0 | -2.427 | 0 | 0.348 |
48 | RP11-161M6.2 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-96-5p | 13 | CCND2 | Sponge network | -1.332 | 0.00015 | -2.427 | 0 | 0.346 |
49 | AC010226.4 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-96-5p | 10 | CCND2 | Sponge network | -1.506 | 0 | -2.427 | 0 | 0.344 |
50 | LINC00565 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 11 | CCND2 | Sponge network | -1.493 | 0.05998 | -2.427 | 0 | 0.342 |
51 | MIR497HG |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p | 16 | CCND2 | Sponge network | -3.802 | 0 | -2.427 | 0 | 0.341 |
52 | LINC00473 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-423-5p;hsa-miR-877-5p | 13 | CCND2 | Sponge network | -5.53 | 0 | -2.427 | 0 | 0.337 |
53 | CTC-378H22.2 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-877-5p | 11 | CCND2 | Sponge network | -1.776 | 0.01283 | -2.427 | 0 | 0.337 |
54 | RP11-1024P17.1 | hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a | 10 | CCND2 | Sponge network | -1.552 | 0 | -2.427 | 0 | 0.336 |
55 | LINC00163 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p | 10 | CCND2 | Sponge network | -4.312 | 0.00014 | -2.427 | 0 | 0.333 |
56 | RP11-326C3.11 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p | 12 | CCND2 | Sponge network | -1.196 | 3.0E-5 | -2.427 | 0 | 0.324 |
57 | AC002480.3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-423-5p | 12 | CCND2 | Sponge network | -1.522 | 0.03484 | -2.427 | 0 | 0.322 |
58 | TP73-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-96-5p | 16 | CCND2 | Sponge network | -1.97 | 0 | -2.427 | 0 | 0.321 |
59 | RP11-456K23.1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-877-5p | 13 | CCND2 | Sponge network | -1.962 | 1.0E-5 | -2.427 | 0 | 0.317 |
60 | AC002480.5 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-378a-3p | 10 | CCND2 | Sponge network | -2.128 | 0.02032 | -2.427 | 0 | 0.312 |
61 | RP11-805I24.3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p | 13 | CCND2 | Sponge network | -5.815 | 0 | -2.427 | 0 | 0.312 |
62 | RP11-356J5.12 |
hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-423-5p | 14 | CCND2 | Sponge network | -2.015 | 0 | -2.427 | 0 | 0.31 |
63 | LINC00327 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-96-5p | 11 | CCND2 | Sponge network | -1.951 | 0.01135 | -2.427 | 0 | 0.306 |
64 | BVES-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-877-5p | 10 | CCND2 | Sponge network | -4.161 | 1.0E-5 | -2.427 | 0 | 0.303 |
65 | RP11-401P9.4 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p | 13 | CCND2 | Sponge network | -2.738 | 0 | -2.427 | 0 | 0.299 |
66 | RP11-403B2.7 | hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p | 10 | CCND2 | Sponge network | -2.507 | 0.00687 | -2.427 | 0 | 0.299 |
67 | RP11-25K19.1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p | 10 | CCND2 | Sponge network | -1.478 | 0.00829 | -2.427 | 0 | 0.298 |
68 | RP11-1008C21.2 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p | 10 | CCND2 | Sponge network | -0.999 | 0.0012 | -2.427 | 0 | 0.294 |
69 | LINC00883 |
hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -0.614 | 0.0511 | -2.427 | 0 | 0.286 |
70 | GATA6-AS1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p | 12 | CCND2 | Sponge network | -3.855 | 0 | -2.427 | 0 | 0.282 |
71 | MIR22HG | hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p | 11 | CCND2 | Sponge network | -1.994 | 0 | -2.427 | 0 | 0.281 |
72 | CTD-2013N24.2 | hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p | 11 | CCND2 | Sponge network | -1.002 | 1.0E-5 | -2.427 | 0 | 0.279 |
73 | DIO3OS | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 15 | CCND2 | Sponge network | -3.619 | 0 | -2.427 | 0 | 0.278 |
74 | RP11-359E10.1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p | 11 | CCND2 | Sponge network | -1.216 | 0.0438 | -2.427 | 0 | 0.276 |
75 | RP11-13K12.5 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-877-5p | 12 | CCND2 | Sponge network | -4.086 | 0 | -2.427 | 0 | 0.275 |
76 | MEG9 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p | 11 | CCND2 | Sponge network | -3.37 | 3.0E-5 | -2.427 | 0 | 0.273 |
77 | RP11-536K7.3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p | 10 | CCND2 | Sponge network | -0.673 | 0.17143 | -2.427 | 0 | 0.272 |
78 | RP11-389G6.3 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-423-5p | 14 | CCND2 | Sponge network | -7.573 | 0 | -2.427 | 0 | 0.272 |
79 | RP4-639F20.1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-96-5p | 12 | CCND2 | Sponge network | -1.492 | 1.0E-5 | -2.427 | 0 | 0.269 |
80 | AC016747.3 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p | 12 | CCND2 | Sponge network | 0.026 | 0.94846 | -2.427 | 0 | 0.267 |
81 | HCG22 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-96-5p | 12 | CCND2 | Sponge network | -2.084 | 0.04175 | -2.427 | 0 | 0.262 |
82 | CTD-2554C21.3 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p | 12 | CCND2 | Sponge network | -2.359 | 0.00283 | -2.427 | 0 | 0.257 |
83 | LINC00982 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p | 13 | CCND2 | Sponge network | -3.353 | 3.0E-5 | -2.427 | 0 | 0.254 |
84 | FLG-AS1 |
hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-877-5p | 14 | CCND2 | Sponge network | -1.812 | 0.00363 | -2.427 | 0 | 0.253 |
85 | RASSF8-AS1 | hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p | 10 | CCND2 | Sponge network | -0.877 | 0.00508 | -2.427 | 0 | 0.253 |